PD-L1 expression

News alerts, weekly reports and conference planners

Entrez ID:

29126

Related biomarkers:

‹

›

PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	pembrolizumab Sensitive: A1 - Approval Pharmabiz - 1 week (New A1) pembrolizumab Sensitive : A1 Pharmabiz - 1wk	pembrolizumab Sensitive: A1 - Approval Pharmabiz - 1 week pembrolizumab Sensitive : A1 Pharmabiz - 1 week - (New A1)
PD-L1 expression	Esophageal Cancer	PD-L1 expression	Esophageal Cancer	pembrolizumab Sensitive: A1 - Approval Pharmabiz - 1 week (New A1) pembrolizumab Sensitive : A1 Pharmabiz - 1wk	pembrolizumab Sensitive: A1 - Approval Pharmabiz - 1 week pembrolizumab Sensitive : A1 Pharmabiz - 1 week - (New A1)
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	tislelizumab Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks (New B) tislelizumab Sensitive : B ASCO-GI 2023 - 2wk	tislelizumab Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks tislelizumab Sensitive : B ASCO-GI 2023 - 2 weeks - (New B)
PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	tislelizumab Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks (New B) tislelizumab Sensitive : B ASCO-GI 2023 - 2wk	tislelizumab Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks tislelizumab Sensitive : B ASCO-GI 2023 - 2 weeks - (New B)
PD-L1 expression	Solid Tumor	PD-L1 expression	Solid Tumor	pembrolizumab + MK-4280 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab + MK-4280 Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab + MK-4280 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab + MK-4280 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	paclitaxel + minnelide Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) paclitaxel + minnelide Sensitive : C3 ASCO-GI 2023 - 2wk	paclitaxel + minnelide Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks paclitaxel + minnelide Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression	Colorectal Cancer	PD-L1 expression	Colorectal Cancer	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2wk	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials J Egypt Natl Canc Inst. - 4 weeks (New C3) Immunotherapy Sensitive : C3 J Egypt Natl Canc Inst. - 4wk	Immunotherapy Sensitive: C3 – Early Trials J Egypt Natl Canc Inst. - 4 weeks Immunotherapy Sensitive : C3 J Egypt Natl Canc Inst. - 4 weeks - (New C3)
PD-L1 expression	Breast Cancer	PD-L1 expression	Breast Cancer	Immunotherapy Sensitive: C3 – Early Trials J Egypt Natl Canc Inst. - 4 weeks (New C3) Immunotherapy Sensitive : C3 J Egypt Natl Canc Inst. - 4wk	Immunotherapy Sensitive: C3 – Early Trials J Egypt Natl Canc Inst. - 4 weeks Immunotherapy Sensitive : C3 J Egypt Natl Canc Inst. - 4 weeks - (New C3)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 expression	Renal Cell Carcinoma	PD-L1 expression	Renal Cell Carcinoma	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	pembrolizumab + bevacizumab Sensitive: A1 - Approval pembrolizumab + bevacizumab Sensitive : A1	pembrolizumab + bevacizumab Sensitive: A1 - Approval pembrolizumab + bevacizumab Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	cemiplimab Sensitive: A1 - Approval cemiplimab Sensitive : A1	cemiplimab Sensitive: A1 - Approval cemiplimab Sensitive : A1
PD-L1 expression	Oral Cancer	PD-L1 expression	Oral Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
PD-L1 expression	Oropharyngeal Cancer	PD-L1 expression	Oropharyngeal Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
PD-L1 expression	Salivary Gland Cancer	PD-L1 expression	Salivary Gland Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
PD-L1 expression	Gastric Adenocarcinoma	PD-L1 expression	Gastric Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
PD-L1 expression	Bladder Cancer	PD-L1 expression	Bladder Cancer	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2
PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2
PD-L1 expression	Bladder Cancer	PD-L1 expression	Bladder Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
PD-L1 expression	Esophageal Adenocarcinoma	PD-L1 expression	Esophageal Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
PD-L1 expression	Renal Cell Carcinoma	PD-L1 expression	Renal Cell Carcinoma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
PD-L1 expression	Head and Neck Cancer	PD-L1 expression	Head and Neck Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
PD-L1 expression	Lung Non-Small Cell Squamous Cancer	PD-L1 expression	Lung Non-Small Cell Squamous Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	bevacizumab + atezolizumab Sensitive: A2 - Guideline bevacizumab + atezolizumab Sensitive : A2	bevacizumab + atezolizumab Sensitive: A2 - Guideline bevacizumab + atezolizumab Sensitive : A2

PD-L1 expression

Associations